News

Proceeds from the financing will be used to advance Eidos' small molecule product candidate, AG10, into Phase 2 clinical trials and to continue preparations for Phase 3 clinical

The Company's proprietary triple combination includes a novel cystic fibrosis transmembrane conductance regulator (CFTR) amplifier, third generation corrector and potentiator, known as PTI-428, PTI-801 and PTI-808, respectively. The

The acquisition is the culmination of a June 2014 alliance between Inception and Roche to discover and develop novel small molecules that promote remyelination of nerve fibers damaged

The company has revealed the top-line results from the phase 3 study of Cyramza as a single agent in the second-line treatment of people with hepatocellular carcinoma (HCC).

Under the deal, the companies will jointly develop OSE-172, which is a SIRP-alpha antagonist targeting myeloid lineage cells. SIRP-alpha is a receptor showed by myeloid lineage cells such

Advanced CCSC is the deadliest non-melanoma skin cancer. Cemiplimab is an investigational human monoclonal antibody targeting the checkpoint inhibitor PD-1 (programmed cell death protein-1). The MAA for cemiplimab

Pfizer views this agreement as an attractive opportunity to support the continued development of allogeneic CAR T therapy in a highly focused and skilled manner. Pfizer will continue

The FDA has accepted AstraZeneca and MedImmune’s biologics license application (BLA) for moxetumomab pasudotox, which is an investigational anti-CD22 recombinant immunotoxin and potential new medicine to treat adult

ALKS 5461 is a proprietary, investigational, once-daily oral medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD) in patients with an